In summary, while irisin shows promise as a diagnostic biomarker and a modulator of tumour progression, its clinical translation will require a concerted effort to standardise methodologies and conduct well-powered, longitudinal studies across diverse cancer types. This evidence concerns the gene FNDC5 and neoplasm.